VT1021

DRUG2 trials

Conditions

GlioblastomaSolid Tumor

Phase 1

Phase 1 Study Evaluating VT1021 in Patients With Advanced Solid Tumors

NCT03364400

Vigeo Therapeutics, Inc.Solid Tumor

Start: 2017-11-28End: 2024-06-30Updated: 2023-05-15

Phase 2

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

RecruitingNCT03970447

Global Coalition for Adaptive ResearchGlioblastoma

Start: 2019-07-30End: 2030-06-01Target: 2250Updated: 2026-05-15

2026-04-14

TIP-10. Update on GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma

Neuro-Oncology2025-11-01

Update on GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma.

Journal of Clinical Oncology2025-05-281 citations

LTBK-02. EVALUATION OF PAXALISIB IN GBM AGILE PHASE 3 REGISTRATION PLATFORM TRIAL FOR NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA

Neuro-Oncology2024-11-012 citations

CTNI-39. UPDATE ON GBM AGILE: A GLOBAL, PHASE 2/3 ADAPTIVE PLATFORM TRIAL TO EVALUATE MULTIPLE REGIMENS IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA

Neuro-Oncology2024-11-01

OS09.7.A GBM AGILE PLATFORM TRIAL FOR NEWLY DIAGNOSED AND RECURRENT GBM: RESULTS OF FIRST EXPERIMENTAL ARM, REGORAFENIB

Neuro-Oncology2024-10-012 citations

KS03.5.A EVALUATION OF VAL-083 IN GBM AGILE, A PHASE 3 REGISTRATION PLATFORM TRIAL FOR NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA

Neuro-Oncology2024-10-01

P27.11.A GLOBAL EXPANSION OF GBM AGILE: A PHASE 2/3 ADAPTIVE PLATFORM TRIAL TO EVALUATE MULTIPLE REGIMENS IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA

Neuro-Oncology2024-10-01

Evaluation of VAL-083 in GBM AGILE, a phase 3 registration platform trial for newly diagnosed and recurrent glioblastoma.

Journal of Clinical Oncology2024-06-011 citations

Phase 1 dose expansion and biomarker study assessing first-in-class tumor microenvironment modulator VT1021 in patients with advanced solid tumors

Communications Medicine2024-05-216 citations

First-in-human phase I dose escalation trial of the first-in-class tumor microenvironment modulator VT1021 in advanced solid tumors.

2024-01-1321 citations

CTNI-85. GBM AGILE PLATFORM TRIAL FOR NEWLY DIAGNOSED AND RECURRENT GBM: RESULTS OF FIRST EXPERIMENTAL ARM, REGORAFENIB

Neuro-Oncology2023-11-0117 citations

P11.29.B UPDATE ON GBM AGILE: A GLOBAL, PHASE 2/3 ADAPTIVE PLATFORM TRIAL TO EVALUATE MULTIPLE REGIMENS IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA

Neuro-Oncology2023-09-01

Immune profiling in patients with glioblastoma treated with VT1021 in a phase I/II expansion study.

Journal of Clinical Oncology2023-06-013 citations

Clinical outcome of biomarker-guided therapies in adult patients with tumors of the nervous system

Neuro-Oncology Advances2023-01-0117 citations

CTNI-27. MULTI-CENTER, PHASE 2 STUDY EVALUATING THE PHARMACOKINETICS, SAFETY AND PRELIMINARY EFFICACY OF PAXALISIB IN NEWLY DIAGNOSED ADULT PATIENTS WITH UNMETHYLATED GLIOBLASTOMA (GBM)

Neuro-Oncology2022-11-011 citations

CTNI-38. UPDATE ON GBM AGILE: A GLOBAL, PHASE 2/3 ADAPTIVE PLATFORM TRIAL TO EVALUATE MULTIPLE REGIMENS IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA

Neuro-Oncology2022-11-01

P11.65.B GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple treatment regimens in newly diagnosed and recurrent glioblastoma

Neuro-Oncology2022-09-011 citations

Paxalisib in patients with newly diagnosed glioblastoma with unmethylated MGMT promoter status: Final phase 2 study results.

Journal of Clinical Oncology2022-06-0124 citations

GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma.

Journal of Clinical Oncology2022-06-017 citations

7 more papers not shown

VT1021

Sponsors

Conditions

Phase 1

Phase 2

Related Papers